New takeover for Allergan: acquires Zeltiq for $2.47bn

A new acquisition has been performed by Allergan, which informed today that it has paid $2.47bn in cash for Zeltiq. Zeltiq owns the CoolSculpting System, which allows to cool and then remove fat cells from tissues, which results in tissue volume reduction. The acquiree was founded in 2008 by two scientists and, according to the 2017 guidance, its revenue will be at least $420m. Zeltiq’s shares rose 13% soon after the acquisition was announced. Allergan keeps pursuing M&A. Indeed, it already announced it had acquired LifeCell for $2.9bn in December and Tobira Therapeutics for $1.7bn in September. (Source Allergan)